Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CloudHealth Announces Genomic Immunotherapy Response Diagnostic

publication date: Feb 27, 2017
CloudHealth Genomics of Shanghai announced a second genomics-based precision medicine test panel, ImmuneSeq Cancer. ImmuneSeq is a 463-gene panel that profiles human response to immunotherapies in all cancer types, with the goal of accelerating drug discovery, therapies and predictive biomarkers. Earlier this year, CloudHealth launched its first panel, HealthySeq, a whole genome next generation sequencing liquid biopsy for healthy individuals. HealthySeq establishes a genomic baseline for an individual and alerts doctors to disease predisposition. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital